Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients.

@article{Gavand2017ClinicalSA,
  title={Clinical spectrum and therapeutic management of systemic lupus erythematosus-associated macrophage activation syndrome: A study of 103 episodes in 89 adult patients.},
  author={Pierre-Edouard Gavand and Ilaria Serio and Laurent Arnaud and Nathalie Cost{\'e}doat-Chalumeau and Julien Carvelli and Antoine Dossier and Olivier Hinschberger and Luc Mouthon and V{\'e}ronique Le Guern and A. C. E. Korganow and Vincent Poindron and Cl{\'e}ment Gourguechon and Christian Lavigne and François Maurier and Guylaine Labro and Marie Heymonet and Matthieu Artifoni and Am{\'e}lie Brabant Viau and Cristophe Deligny and Thomas Sen{\'e} and Louis Terriou and Jean Sibilia and Alexis Mathian and Coralie Bloch-Queyrat and Claire Larroche and Zahir Amoura and Thierry Martin},
  journal={Autoimmunity reviews},
  year={2017},
  volume={16 7},
  pages={743-749}
}
OBJECTIVES Macrophage activation syndrome (MAS) is a life-threatening hyperinflammatory syndrome that can occur during systemic lupus erythematosus (SLE). Data on MAS in adult SLE patients are very limited. The aim of this study is to describe the clinical characteristics, laboratory findings, treatments, and outcomes of a large series of SLE-associated MAS. METHODS We conducted a retrospective study that included 103 episodes of MAS in 89 adult patients with SLE. RESULTS 103 episodes in 89… CONTINUE READING